Food
Jonathan Gold's 101 Best Restaurants: The list is here

Hepatitis

Gilead says drug profits must stay high to pay for 'innovation,' but 100% of its profits went to shareholders

Gilead says drug profits must stay high to pay for 'innovation,' but 100% of its profits went to shareholders

With high drug prices still in the political crosshairs on Capitol Hill, pharmaceutical industry bosses are at pains to explain why a cure for hepatitis-C has to cost a budget-busting $1,000 per pill, or a promising cancer treatment should carry a list price of $373,000.

That duty most recently fell to John C. Martin, the executive chairman of Gilead Sciences, which happens to be the owner of both of those stratospherically priced drugs. In an interview

EDITION: California | U.S. & World
89°